CD274 and non-small cell lung carcinoma: Similarly, in the phase 2 HUDSON umbrella study in patients with NSCLC post anti-PD-L1 and platinum-doublet therapy, durvalumab–ceralasertib combination demonstrated superior efficacy compared to other regimens; responses were particularly pronounced in patients with ATM alterations, correlative biomarker analyses revealed downregulation of monocyte, CD8+ T cell, and exhaustion-associated gene signatures along with upregulation of TNF-α, interferon-γ, and interferon-α pathways (Besse et al., 2024).